All animal protocols (AUA 17-032, 18-097, and 19-0102) were approved by the UTHSC IACUC prior to the start of any of the experiments. Author contributions FP and MMY conceived the idea and designed the study. of G2/M blockade (phosphorylated histone H3 Ser10 and cyclin B1), and apoptosis (cleaved caspase-3). Conditional proximal tubuleCexpressing mice were observed to be virtually protected from the cisplatin nephrotoxicity by restoring most of Mouse monoclonal to Ractopamine the pathological phenotypes back toward normal conditions. Our findings suggest that TRIP13 could circumvent DNA damage in the proximal tubules during cisplatin injury and that TRIP13 may constitute a new therapeutic target in protecting the kidney from nephrotoxicants and reduce outcomes leading to AKI. can increase cell cycle blockade at the G2/M phase (23) and inefficiently repair double-stranded DNA breaks (16, 24, 25), which leads to the activation of apoptotic cell death pathways in germline and somatic cells (16, 23C25). Moreover, TRIP13 directly activates DNA-dependent protein kinase catalytic subunit (DNA-PKcs), which Ginsenoside Rg1 is a primary enzyme involved in the nonhomologous end joining (NHEJ) pathway of double-stranded DNA repair, to promote tumorigenesis (23). In the kidney, global hypomorph mice exhibit prolonged tubular epithelial cell damage following bilateral ischemia/reperfusion injury, which is associated with increased DNA damage and activated apoptotic signaling (26). To date, however, the role of TRIP13 to prevent tubular damage in other forms of AKI, such as cisplatin nephrotoxicity, with respect to double-stranded breaks has yet to be Ginsenoside Rg1 studied. In the present study, pharmacological inhibitors targeting double-stranded DNA repair pathways were tested to determine any interference in the normal recovery of damaged renal tubules due to cisplatin. To determine whether TRIP13 could modulate this process, a transgenic mouse model was generated to conditionally overexpress using the GGT1-Cre recombinase, since the main segment of cisplatin nephrotoxicity is the proximal tubules. The transgenic mice appeared normal with no evidence of any abnormal renal morphology or function. In the face of AKI following cisplatin administration, the sites, which were placed between the CAG promoter and the transgene cassette (overexpression.(A) Targeting construct was designed for integration into the ROSA26 region, and the expression cassette was designed with the CAG promoter-floxed stop codon-Trip13 cDNA-T2A-EGFP-polyA. 2A, protease cleavage site (cDNA was FLAG tagged at the 3 end); CAG, CMV-IE enhancer/chicken -actin/rabbit -globin. (B) Genomic DNA isolated from mouse pups was PCR analyzed using specific primers to differentiate wild-type, floxed stop, and Cre-containing mice. Wild-type (WT) = 453 bp; floxed stop (flox) = 616 bp; and Cre = 400 bp. M = 1 kb ladder; lanes 1, 4, and 7 = Ginsenoside Rg1 F1/R1 primers (wild-type); 2, 5, and 8 = F2/R1 primers (floxed Trip13); and 3, 6, and 9 = GGT1-Cre primers (Cre); erthyroagglutinin; DBA, agglutinin. Table 1 PCR primers for genotyping Open in a separate window Phenotyping of the mice was performed by detecting FLAG-tagged TRIP13 and GFP Ginsenoside Rg1 by European blot analysis using protein lysates from harvested organs from female overexpression in the proximal tubules provides safety from renal tubular epithelial cell damage following cisplatin administration.Mice were injected with a single injection of vehicle (20% captisol in saline) or cisplatin (15 mg/kg IP), and kidneys and blood were harvested to detect markers of renal dysfunction. (A) Kidney samples from homozygous floxed stop ( 0.05, **** 0.0001 between all other organizations using 1-way ANOVA with Tukeys post hoc analysis. = 4C8 animals per group. Level pub: 200 m (ECH). In our initial study group, no significant difference in body weight was measured in both = 11) and 72 hours (= 6) following vehicle treatment (data not demonstrated). At 24 hours, there was a moderate 5.4% decrease in body weight after which the body pounds slightly improved above the pretreatment pounds by 7.4% at 72 hours. At 24 and 72 Ginsenoside Rg1 hours following cisplatin treatment, the body excess weight in the = 11) and 25.1% (= 6), respectively, compared with pretreatment measurements, whereas the mice treated with cisplatin (1.95 0.32 mg/dL; = 6) compared with vehicle-treated littermates (0.11 0.1 mg/dL; = 6; Number 2B). In the constitutive proximal tubule TRIP13-expressing (= 8) mice following cisplatin administration,.